Increased Anticholinergic Agent Use With Co-prescription of CYP2D6-Inhibiting SSRIs and Risperidone, but not Aripiprazole: A Nationwide Cohort Study
Co-prescription of strong CYP2D6-inhibiting SSRIs with risperidone, but not aripiprazole, is associated with a significant increase in anticholinergic use, providing large-scale, real-world evidence of a clinically meaningful DDI. These findings underscore the importance of considering SSRI metabolic profiles to mitigate EPS risk in patients treated with risperidone.
Authors
- Yil‐Seob Lee (ORCID: https://orcid.org/0000-0002-4597-5990)
- Hyounggyoon Yoo (ORCID: https://orcid.org/0000-0003-2785-4383)
- Wonsuk Shin (ORCID: https://orcid.org/0000-0002-6163-5726)
- Sra Jung (ORCID: https://orcid.org/0000-0001-5510-0680)
- Min‐Kyoung Kim (ORCID: https://orcid.org/0000-0002-5596-5665)
- M.K. Hong (ORCID: https://orcid.org/0009-0004-0646-4989)
- Dong Hyeon Lee
Institutions
- Samsung Medical Center (KR)
- CHA University Bundang Medical Center (KR)
- CHA University (KR)
Publication Details
- Journal
- Schizophrenia Bulletin
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1093/schbul/sbaf189
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00